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Abstract
Introduction and hypothesis Polyacrylamide hydrogel
(PAHG, Bulkamid®) is a promising urethral bulking agent.
This article presents the 2-year follow-up results of a mul-
ticenter study of PAHG injections for treating stress and
stress-predominant mixed urinary incontinence.
Methods Submucosal injection of PAHGwas performed in 135
women with urinary incontinence, with subjective and objective
assessment of the efficacy and safety 24 months postinjection.
Results At 24 months, the subjective responder rate was
64% (a statistically non-significant reduction from 67% at
12 months). The decreased number of incontinence episodes
and urine leakage were maintained compared with the result
from the 12-month evaluations, as were objective result
rates and quality of life data. No safety issues occurred.
Conclusions PAHG is an effective and safe treatment option
for women with stress-predominant mixed urinary inconti-
nence, with maintained medium-term responder rates.
Keywords Bulking . Mixed incontinence . Stress .
Polyacrylamide hydrogel . Bulkamid
Introduction
Bulking agents were first described for treating stress urinary
incontinence (SUI) more than 100 years ago [1] as a minimally
invasive method to treat urinary incontinence (UI). Since that
time, many bulking agents of different makes and tissue inter-
actions have been used to treat UI. However, in the intervening
period, many substances have been tried and abandoned due to
concerns with both efficacy [2] and safety [3–9]. The mecha-
nism of action of urethral bulking is not yet fully understood.
One hypothesis is that intraurethral bulking produces coaptation
of the urethral edges during the storage phase of the micturition
cycle and particularly during periods of increased abdominal
pressure [2]. Studies describing increased abdominal pressure
transmission in the first quarter of the urethra [10] and increased
abdominal leak-point pressure as a result of successful urethral
injection outcomes [11] would support this hypothesis. Inject-
able agents therefore were thought to restore continence by
increasing urethral resistance only at rest and allowing the
urethra to funnel and open during micturition [12]. This theory
was challenged by the publication of an alternative explanation
of the mechanism of action [11, 13] whereby it was suggested
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that if positioned appropriately, the bulking agent could create a
zone of increased contractility of the rhabdosphincter by creat-
ing an increased stretch of the muscle fibers. This theory pro-
posed a possible mechanism whereby increase in the active
component of the urethral pressure profile after bulking was
explained. These two theories are not, of course, mutually
exclusive, and there may be a combined mechanism.
The first description of the use of polyacrylamide hydrogel
(PAHG) for urethral bulking was in 2006 [14]. Bulkamid® is a
polymer gel consisting of 2.5% cross-linked polyacrylamide and
97.5% water for injection. It is atoxic [15, 16] and resistant to
degradation [17, 18]. PAHG has been used in aesthetic plastic
and reconstructive surgery in Europe for the past 7 years, and
long-term as well as experimental studies show that the gel is
gradually integrated through a fine network of vessel-bearing
connective tissue, with no capsular fibrosis or calcification.
Tissue integration starts immediately after implantation and is
completed approximated 12-months post-injection depending
on the bulk size [17–20]. The 12-month results of this study
were previously presented, and they confirmed a 67 % subjec-
tive response rate, with a reduction in both incontinence episodes
and 24-h pad weights [21]. The aim of the paper presented here
was to assess the effectiveness and safety 2 years post PAHG
injection in women with SUI or mixed UI (MUI) as a secondary
endpoint to the initial presentation of the 1-year data.
Materials and methods
The study was an open, noncomparative, multicenter, mul-
tinational study involving ten centers from five countries:
two in Denmark, two in Sweden, one in Finland, four in the
UK, and one in Germany. The materials and methods for
this study were previously described in detail [21].
Patient characteristics
Women aged ≥18 years with symptomatic SUI or MUI were
eligible to participate. Inclusion criteria were duration of
symptoms (≥12 months) and incontinence episode frequen-
cy (≥1 per 24 h). Additional requirements were a maximum
flow rate of ≥15 ml/s, a postvoid residual urine volume
(PVR) of ≤100 ml, a bladder capacity of ≥300 ml, and
normal diuresis (<40 ml/kg per 24 h). Exclusion criteria
were pelvic organ prolapse (POP) ≥stage 2; an acute urinary
tract infection (UTI); allergic reaction to local anesthesia
and antibiotics used for prophylaxis; previous surgery for
incontinence, including bulking; ongoing medication for
incontinence (except anticholinergics at a constant dose for
>4 weeks); treatment with systemic corticosteroids; active
autoimmune or connective tissue diseases; or pregnancy.
All women had a screening visit involving full medical
history, physical and pelvic examination including genital
prolapse (POP quantification) score, uroflowmetry, PVRmea-
surement, and urine dipstick test (if positive with culture and
sensitivity). The screening visit was followed by a baseline
visit for collecting data from the 24-h pad-weighting test and
3-day micturition diary, including bladder capacity, number of
micturitions, number of SUI and urge incontinence (UUI)
episodes, and estimated renal output. Participants were also
asked to complete the International Consultation on Inconti-
nence Questionnaire (ICIQ) [21, 22] and a patient quality of
life (QoL) and visual analogue scale (VAS) score [23]. Treat-
ment with PAHGwas performed at the baseline visit or within
3 days and no later than 8 weeks from the screening visit.
Treatment and follow-up
PAHG injection was performed under local anesthesia (10 ml,
5% lidocaine injected into the urethral wall). PAHG was
injected under urethroscopic control transurethrally into the
submucosa (three deposits of 0.2–0.8 ml each, 0.5–1 cm distal
to the bladder neck) using a 23-gauge × 120-mm needle with
1-cm markings to ensure correct depth of injection placement.
After satisfactory urethral occlusion, the bladder was emptied
via the endoscope. During injection, the women received a
single dose of prophylactic antibiotic treatment dependent on
local protocol. Women were discharged after successful void-
ing (PVR <100 ml, assessed by bladder scanning). They were
re-evaluated, as previously described [21], at 1 and 6 months,
with 12-month follow-up as the primary endpoint. This paper
presents the secondary endpoint of the extended 24-month
follow-up. The 24-month visit efficacy assessment included
patients’ subjective perception (cured, improved, not changed,
or worsened) [24]. Objective assessment included 3-day mic-
turition diary assessment for the number of incontinence epi-
sodes per 24 h and 24-h pad-weighting testing. Urine dipstick
and PVR measurement were performed during the visit. QoL
assessment wasmade by repeating the ICIQ and VAS score on
QoL. Subjective responders were defined as women consid-
ering themselves as cured or improved. Women not respond-
ing to the initial injection were offered a second treatment
between 6–8 weeks after the first injection. Adverse events
(AE) were classified as serious or nonserious and judged to be
either related (ADE) or unrelated (AE) to the study treatment.
Data analyses and statistics
All analyses were carried out in identical fashion to those
reported in the previous publication [21] and are therefore
only described briefly. All analysis was based on the
intention-to-treat (ITT) analysis set, which was defined as
patients who received at least one treatment. ITT data were
interpreted as described by Hollis and Campbell [25] and in
keeping with other similar studies on bulking agents [26].
The sample size of 100 was estimated assuming a 50%
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success rate, with a maximum of uncertainty of 10%. As-
suming a dropout rate of 20%, a target of 125 participants
was required. The primary end point for this calculation was
the 12-month data previously reported [21]. This data set
represents the secondary endpoint of 24 months. Detailed
descriptions of the analysis on ICIQ scores, urine leakage
(pad test), number of incontinence episodes, and VAS scores
measuring QoL have previously been published [21].
Additional analyses
Additional analyses were performed to evaluate the effect of
other variables in the treatment outcome. Responder rate
was assessed on data sets stratified by type of incontinence
(stress vs mixed), number of treatments (one vs two), and
number of procedures performed per center [<15 injections
(low volume) vs ≥15 (high volume)]. As supportive analysis
of the primary analysis, the logistic regression model was
expanded by incorporating the covariates age and body
mass index (BMI) as continuous variables in separate
analyses.
Ethical assurances
The study was performed in accordance with the International
Conference on Harmonization Good Clinical Practice Guide-
lines; in accordance with the Declaration of Helsinki II, 1964,
as amended in Scotland, October 2000; the Council Directive
93/42/EEC concerning medical devices; and the International
Organization for Standardization/Draft International Standard
(ISO/DIS) 14155-1+2:2003 Clinical investigation of medical
devices for human subjects. The clinical investigation plan
was submitted to all local ethics committees. Written consent
was obtained from all patients after written and verbal infor-
mation about the study, procedures, potential risk or incon-
veniences, and expected benefits.
Results
One hundred thirty-five women (67 with SUI and 68 with
MUI) were recruited and treated with PAHG. Patients’ demo-
graphic and incontinence-related characteristics were previous-
ly described [21]. Eighty-eight patients (65%) had one
treatment and 47 (35%) received a second on request. The
mean of total injected volume was 1.53 ml [standard deviation
(SD) 0.48 ml], and the median volume per deposit was 0.5 ml.
The median time spent on the injection procedure was 7 (range
2–20) min. Eighty-six women (64% of the original cohort)
were available for the 24-month follow-up. Of the with-
drawals, one patient had an AE (aggravated UI), three with-
drew consent, 30 reported lack of effect (eight went on to have
further surgery, all being retropubic tapes), four previously
successful patients were not included in the analysis because
they withdrew >6 months before the 24-month assessment,
and one patient was included as a responder who missed the
12-month analysis but attended the 2-year follow-up. One
hundred and thirty-five patients were initially included in the
intention to treat analysis. Following the rules described for last
observation carried forward (LOCF) and imputation results for
subjective outcome are presented for 124 patients at 12 months
and 116 patients at 24 months. Table 1 shows the subjective
success rates as both per protocol and intention to treat. On the
intention to treat analysis at 24 months, the success rate was
Table 1 Subjective success rates at 1, 6, 12, and 24 months after
treatment
1 month 6 months 12 months 24 months
ITT (patients) 135 129 124 116
Responders % 87% 71% 67% 64%
CI 81–92% 62–78% 58–72% 55–72%
ITT intention to treat, CI confidence interval
Fig. 1 International Consultation
on Incontinence Questionnaire
(ICIQ) scores at 1, 6, 12, and
24 months [intention to treat
(ITT) analysis]. Question 1:
How often do you leak urine?
(range 0–5). Question 2: How
much urine do you usually leak?
(range 0–6). Question 3:
How much does leaking urine
interfere with your everyday life?
(range 0–10)
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maintained at 64% (which was a nonstatistically significant
reduction from 67% at 12 months). Twenty (17%) were cured
and 54 (47%) improved. Of the responding patients at
12 months, 94% (116/124) had sustained success rates at the
24-month follow-up.
The slight deterioration seen with the subjective outcome is
not recorded in either the ICIQ (Fig. 1) or VAS (Fig. 2) scores,
where the improvement measured 12months after treatment is
maintained. Similarly, in the objective outcomes, both incon-
tinence episode frequency and pad-weight test results retained
the initial improvement. Results show a significant decrease in
the number of incontinence episodes (p<0.0001, Table 2) as
well as a significant reduction in leakage from baseline to
24months (p<0.0001, Table 3). Consistent with the 12-month
results, there was a nonstatistical trend toward a slightly better
outcome for patients with “pure” SUI rather than MUI (69%
vs 58%).
In terms of response to repeat treatment, the estimated
responder rate was 69% in patients receiving only one
treatment and 53% in patients receiving two treatments.
Compared with the responder rates at 12 months follow-up
(one treatment 72%; two treatments 57%), the differences
were borderline statistically significant (p00.081)
Safety evaluation
At the 24-month follow-up, 16 new nonserious AEs and
four new serious adverse reactions were reported, none of
which was thought to be related to the treatment. No woman
had signs of impaired bladder emptying based on postvoid
residuals at 24 months.
Discussion
The evidence of medium/long-term durability and safety of
different bulking agents is limited. We report the first sys-
tematic 2-year follow-up of PAHG (Bulkamid®) injection
for SUI and MUI. The response rate of 67% after 12 months
(cured or improved) was sustained, which was supported by
objective findings of 24-h pad-weighting test, number of
incontinence episodes, and QoL data. Furthermore, no safety
issues occurred between 1 and 2 years’ follow-up. The find-
ings are in good agreement with a study by Ghoniem et al.
that showed 88% durability success and few complications
after 2 years [27]. In contrast, two studies on transurethral
injection of hyaluronic acid/dextranomer (NASHA/Dx gel)
showed poor durability of effect and a high incidence of
complications [28, 29].
PAHG and Macroplastique® (silicone-based) are nonre-
sorbable and nondegradable bulking agents. After injection
with these gels, the foreign-body reaction is mild (PAHG) to
modest (Silicone). Silicone, however, is hydrophobic and
has a tendency to migrate from the implantation site via
circulating phagocytic cells [30, 31] in contrast to PAHG,
which is hydrophilic. Moreover, PAHG will interact with
Fig. 2 Patient quality of life
visual analog scale (VAS) scores
over timer in the intention to treat
(ITT) analysis set
Table 2 Urinary leakage (pad test) over time
Baseline 1 month 6 months 12 months 24 months
Mean leakage (g)
Mean (SD) 54.3 (78.1) 20.8 (49.2) 14.6 (23.3) 10.9 (19.0) 13.2 (28.1)
Median 28.5 4.0 5.3 3.8 3.0
Leakage is the 24-h leakage measured as mean over 2 days
SD standard deviation
Table 3 Summary of daily incontinence episodes over time
Baseline 1 month 6 months 12 months 24 months
Mean (SD) 3.68 (2.5) 1.78 (2.7) 1.81 (2.6) 1.55 (2.7) 1.53 (2.8)
Median 3.00 0.67 0.67 0.67 0.50
Daily number of incontinence episodes is the mean over 3 days
registered in the patient’s diary
SD standard deviation
1376 Int Urogynecol J (2012) 23:1373–1378
the surrounding tissue as a consequence of the high water
content and structure and integrate into the surrounding
tissue through a fine network of vessel-bearing connective
tissue, thus being firmly anchored into the surrounding
tissue. Analysis of cost effectiveness suggests that the de-
cline in the use of bulking agents may be premature and that
there may be a valid economic argument to consider their
use [32]. Advantages of bulking agents are ease of applica-
tion, which can be achieved in the office setting, and a
reduced side effect/complication risk for patients, where this
is the more pressing part of the risk–benefit ratio.
This study, as with many others, has continued to supply
evidence demonstrating that PAHG in pure SUI tend to
achieve better outcomes than those for MUI [14, 33]. How-
ever, as with other surgeries, this treatment method may lead
to improvement in QoL as a result of decreased symptoms,
rather than cure, and as such may have a valuable therapeu-
tic role within stress-predominant MUI. In our previous
paper [21], the potential mechanisms of action were dis-
cussed. No attempt at site assessment or implant action was
made during this study, and so no conclusion can be made as
to the mode of action. It would seem logical, given the
length of the urethra, that both mechanisms may be in-
volved, and further assessment of placement site and suc-
cess may be of value.
Safety concerns have been raised regarding specific bulking
agents because of migration, hypersensitivity, urethral erosion,
pseudocysts/abscess, granuloma formation, and obstruction
[3–9, 28, 29]. All AEs recorded after PAHG injection were
generic and not related to the material. No treatment-related
AEs were reported by the investigators during follow-up from
12 to 24 months.
Indications for using bulking agents to treat UI remain a
contentious issue. In one publication, the cure rate of a
repeat midurethral sling was significantly lower and the
incidence of de novo urgency and UUI was significantly
higher in repeat procedures [34]. Urethral bulking may
therefore be an alternative to repeat midurethral sling
procedures.
Conclusions
This report presents the largest series in a powered study
demonstrating medium-term longevity of PAHG treatment
of UI, with no trend toward a decrease in efficacy at 2 years.
The reason for this is almost certainly related to the proper-
ties of the polyacrylamide implant, in which the bulking
substance is made up predominantly of water held within
the polyacrylamide gel matrix. The substance is unlikely to
migrate, and indeed, there are no reported cases of this in
any of the applications in medicine in over 20 years of use.
Secondly, there are no reported AEs, such as granuloma or
abscess formation, suggesting that the substance remains
inert, does not metabolize, and as such maintains shape
and size. We therefore conclude that these properties are
central to the results achieved in this series 2 years post-
treatment. These results confirm PAHG to be an easy and
safe bulking agent for treating uncomplicated SUI or MUI,
with favorable durability 2 years after injection.
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